Topics
Glioblastoma | Treatment | Targeted therapy | Pazopanib
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Pazopanib
Ozer BH, Cohen AL, Colman H, Penas-Prado M, de Groot J, Loghin ME,
Pan E, Raizer JJ, Kumthekar P, Fink KL, Walbert T, Merrell RT,
Groves MD, Ahluwalia MS, Wu J, Burton EC, Vera E, Mendoza T,
Grajkowska E, Wall K, Reyes J, Yuan Y, Armstrong TS, Gilbert MR.
Combination of metronomic oral
pazopanib and topotecan for recurrent glioblastoma with and
without previous bevacizumab: Results from a phase 2 clinical
trial.
Neurooncol
Adv. 2026 Jan 23;8(1):vdaf261. doi:
10.1093/noajnl/vdaf261. PMID:
42028236. Trial
registration ID: NCT01931098. ˍ